James N. Ingle

Mayo Clinic — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

94h-index54.1kcitations721works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(253), Breast Cancer Treatment Studies(196), Cancer Treatment and Pharmacology(108), HER2/EGFR in Cancer Research(96), Advanced Breast Cancer Therapies(85)

Publications720 total

Supplementary Table S6 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Table S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Table S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Table S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Table S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Table S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
2025Open Access
Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
2025Open Access
Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
2025Open Access
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial
npj Breast Cancer·2025Open Access
Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer”
Journal of Clinical Oncology·2025· 1 cited
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole
Breast Cancer Research and Treatment·2025Open Access
Abstract P1-07-06: Adjunctive statistical standardization of quantitated adjuvant HER2 and very low statistically standardized HER2 in CCTG MA.27
Clinical Cancer Research·2025
Abstract PS12-07: DNA methyltransferase 3A (DNMT3A) protein expression in triple-negative breast cancer (TNBC): Impact on clinical outcomes, gene expression, and tumor microenvironment
Clinical Cancer Research·2025
Abstract P2-12-18: A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2-Breast Cancer (EVANGELINE)
Clinical Cancer Research·2025
Abstract P1-11-04: Neoadjuvant Z-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor (HER2)- Breast Cancer (BC): Evaluation of the Pharmacokinetic (PK) Run-in for the EVANGELINE Study
Clinical Cancer Research·2025
Abstract P3-05-29: Seven in Absentia Homolog (SIAH) expression and clinicopathological correlates in early-stage triple-negative breast cancer (TNBC)
Clinical Cancer Research·2025
Abstract P2-03-07: Neoadjuvant (Z)-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor 2 (HER2)- Breast Cancer (BC): Evaluation of Quality of Life (QOL) measures in the EVANGELINE Study
Clinical Cancer Research·2025
page 1 of 36Next →

Frequent Co-authors

Nancy E. Davidson(18), Silvana Martino(16), Edith A. Perez(15), Eric P. Winer(12), Kathleen I. Pritchard(12), Hyman B. Muss(10), Richard D. Gelber(9), Clifford A. Hudis(9), Alan S. Coates(8), Martine Piccart(8), Dongsheng Tu(8), Lois E. Shepherd(8), Aron Goldhirsch(7), Larry Norton(7), Julie R. Gralow(7), Vera J. Suman(6), Daniel W. Visscher(6), Wilma L. Lingle(6), Harold J. Burstein(6), Daniel F. Hayes(6)